Dedicated to making life better for people living with underserved disorders with high unmet medical needs.
Location: United States, Alabama, Satsuma
Phone: +1 484-713-6133
Total raised: $187.8M
Investors 2
| Date | Name | Website |
| 18.07.2021 | Valor Equi... | valorep.co... |
| - | Horizon Te... | horizontec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.05.2022 | - | $112.8M | - |
| 25.03.2020 | - | $75M | - |
Mentions in press and media 6
| Date | Title | Description |
| 21.07.2022 | Many Productive Developments for Jeff Aronin’s Paragon Biosciences’ Portfolio Companies in the First Half of 2022 | David Thompson, Tech Times 21 July 2022, 11:07 am (Photo : Paragon Biosciences) Jeff Aronin's Paragon Biosciences and its portfolio companies have seen great growth in the first two quarters of 2022 on its mission to find innovative treatme... |
| 10.01.2022 | Castle Creek Biosciences Acquires Novavita Thera to Expand Innovative Cell and Gene Therapy Platform | EXTON, Pa., Jan. 10, 2022 /PRNewswire/ -- Castle Creek Biosciences, Inc., a late-clinical stage cell and gene therapy company focused on developing and preparing to commercialize disease-modifying and potentially curative therapies for rare... |
| 29.09.2021 | Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic | EXTON, Pa., Sept. 29, 2021 /PRNewswire/ -- Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for wh... |
| 11.05.2021 | Jeff Aronin Announces Matthew Gantz as CEO of Castle Creek Biosciences | Share Tweet Share Share Email Castle Creek Biosciences recently announced the appointment of Matthew Gantz as the organization’s President and Chief Executive Officer. The appointment will also include a position on the board of directors f... |
| 25.03.2020 | Castle Creek Biosciences Raises $75M in Funding | Castle Creek Biosciences, Inc., an Exton, Pa.-based late-stage gene therapy company, received $75m in equity and debt funding. Paragon Biosciences led the $55m equity investment with participation from Fidelity Management & Research Com... |
| - | Castle Creek Biosciences | “Dedicated to making life better for people suffering from rare diseases with few or no treatment options” |